Henry Schein (HSIC) Receives Hold Rating from Leerink Swann

Henry Schein (NASDAQ:HSIC)‘s stock had its “hold” rating reissued by analysts at Leerink Swann in a research note issued to investors on Tuesday.

Several other equities analysts also recently commented on HSIC. Stephens assumed coverage on Henry Schein in a research report on Tuesday, November 28th. They issued an “equal weight” rating and a $76.00 target price on the stock. Jefferies Group reaffirmed a “hold” rating and issued a $89.00 target price on shares of Henry Schein in a research report on Friday, October 20th. Robert W. Baird set a $95.00 target price on Henry Schein and gave the company a “buy” rating in a research report on Thursday, October 19th. TheStreet downgraded Henry Schein from a “b” rating to a “c+” rating in a research report on Monday, November 6th. Finally, Stifel Nicolaus decreased their target price on Henry Schein from $89.00 to $77.00 and set a “hold” rating on the stock in a research report on Tuesday, November 7th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and eight have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $84.23.

Shares of Henry Schein (NASDAQ HSIC) opened at $72.18 on Tuesday. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.55 and a quick ratio of 0.86. The stock has a market capitalization of $11,261.48, a P/E ratio of 20.80, a price-to-earnings-growth ratio of 1.84 and a beta of 1.00. Henry Schein has a 52 week low of $65.28 and a 52 week high of $93.50.

In related news, Director Barry J. Alperin sold 5,796 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $70.76, for a total transaction of $410,124.96. Following the sale, the director now owns 48,172 shares of the company’s stock, valued at $3,408,650.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.19% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. Steinberg Global Asset Management lifted its stake in Henry Schein by 100.0% during the third quarter. Steinberg Global Asset Management now owns 19,412 shares of the company’s stock worth $1,592,000 after purchasing an additional 9,706 shares during the last quarter. Janus Henderson Group PLC lifted its stake in Henry Schein by 92.1% during the third quarter. Janus Henderson Group PLC now owns 2,814,636 shares of the company’s stock worth $230,777,000 after purchasing an additional 1,349,333 shares during the last quarter. Catalyst Capital Advisors LLC bought a new stake in Henry Schein during the third quarter worth $287,000. Neuberger Berman Group LLC lifted its stake in Henry Schein by 95.9% during the third quarter. Neuberger Berman Group LLC now owns 2,475,058 shares of the company’s stock worth $202,930,000 after purchasing an additional 1,211,743 shares during the last quarter. Finally, Swedbank lifted its stake in Henry Schein by 84.9% during the third quarter. Swedbank now owns 2,358,594 shares of the company’s stock worth $193,381,000 after purchasing an additional 1,083,115 shares during the last quarter. 91.15% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This story was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.americanbankingnews.com/2018/02/13/henry-schein-hsic-receives-hold-rating-from-leerink-swann.html.

Henry Schein Company Profile

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Analyst Recommendations for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply